Below are some key points highlighted in connection with the report:

• Progress in the clinical development within erythromelalgia and obesity
• Incomplete preclinical results within obesity
• Agreement with a new CRO to prepare and submit a clinical trial application within obesity
• Stable cash position – amounted to SEK 19.3m at the end of H2-25

In summary, Pila Pharma is maintaining a high operational pace, with completed preclinical studies and initiated preparations for clinical development in both erythromelalgia and obesity, while also expected to continue clinical development in type 2 diabetes, which together constitute strong potential value drivers going forward. We view XEN-D0501 as a scalable candidate offering a differentiated alternative compared to current therapies across the various indications. However, to accelerate clinical development according to plan, additional external capital is expected to be required, with the outcome of the TO2 warrants becoming important for the extent of any future financing needs.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
 
This is a press release from Analyst Group regarding the publication of a comment on Pila Pharma. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.